CERC Cerecor Inc.

0.57
+0.02  (4%)
Previous Close 0.55
Open 0.53
Price To book 0.00
Market Cap 8.03M
Shares 14,081,000
Volume 118,059
Short Ratio 2.42
Av. Daily Volume 296,808

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 trial planned.
CERC-501
Major depressive disorder (MDD)
Phase 2 top-line data released December 5, 2016 - endpoint not met.
CERC-501
Smoking cessation
Phase 2 top-line data released November 29, 2016 failed to meet primary endpoint.
CERC-301
Major depressive disorder (MDD)

Latest News

  1. Cerecor to present at the American Society for Clinical Psychopharmacology Conference
  2. Cerecor Appoints Steven Boyd and Peter Greenleaf to Board of Directors
  3. CERC: Encouraging Results from Proof-of-Concept Study of CERC-501 in MDD
  4. Cerecor Inc. Reports First Quarter 2017 Financial Results
  5. Cerecor Reports Encouraging Topline Data from a NIH Sponsored Proof-of-Concept Trial of CERC-501 in Treatment-Resistant Depression
  6. Cerecor Inc. Closes $5.0 Million Private Placement
  7. CERC: Ready to Move Ahead With Phase 2/3 Study of CERC-501 in MDD
  8. Cerecor Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
  9. Cerecor Engages SunTrust Robinson Humphrey to Assist with Review of Strategic Alternatives
  10. Cerecor Announces At-the-Market Equity Offering Program
  11. Cerecor Nicotine Withdrawal Drug Fails Study (CERC)
  12. Cerecor Inc (CERC)’s Trial Failure Isn’t All Bad, Here’s The Silver Lining
  13. CERC: CERC-501 Not Successful in Nicotine Withdrawal; Preparing for Phase 2/3 Study of CERC-501 in MDD
  14. Cerecor Announces Top-Line Results from CERC-501 Phase 2 Study for Nicotine Withdrawal
  15. Cerecor Depression Drug Fails Phase 2 Trial (CERC)
  16. CERC: CERC-301 Fails to Show Benefit in MDD in Phase 2 Clinical Trial; Attention Now Turns to CERC-501
  17. Cerecor Reports Top-Line Data from CERC-301 Phase 2 Study for Major Depressive Disorder
  18. CERC: Results from Phase 2 Study of CERC-301 in Major Depressive Disorder to be Announced in November 2016